Warning Letters | FDA
FDA issued two new warning letters for CGMP violations in finished pharmaceuticals, indicating increased enforcement that may extend to dietary supplements.
Aforeworn detected this change in the Dietary-Supplement Labeling (FDA) space on July 7, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers should confirm how it applies to their specific situation before acting. There is a time constraint attached: Within 30 days. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Dietary-Supplement Labeling (FDA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Two new warning letters issued to Excelvision - Fareva and Wizcure Pharmaa Private Limited for CGMP/Finished Pharmaceuticals/Adulterated violations.
Who it affects
Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers
What you must do
Review your own CGMP compliance and ensure labeling and manufacturing practices meet FDA standards.
Deadline
Within 30 days
Never miss a change like this again
Aforeworn watches Dietary-Supplement Labeling (FDA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Dietary-Supplement Labeling (FDA)
- FDA Advisory No.2026-0735 || Public Health Warning on the Presence of Sildenafil Citrate in TURBO Maca and Clavo Huasca Dietary Supplement Capsules for Men with Lot Number 24TRB1102 - fda.gov.ph
- Warning Letters | FDA
- FDA Advisory No.2026-0162-A || Lifting the Advisory on the Registered Food Product LUXE SKIN BEAUTY TALKS L’ANNA Premium Oral Sunblock + Stem Cell Dietary Supplement “Public Health Warning Against the Purchase and Consumption of the Unregis - fda.gov.ph
- The Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls - Food and Drug Law Institute (FDLI)
- 60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement - GlobeNewswire